Showing results (141-150 of 175) with videos related to

Sort By:
Pageof 18
Cancer Science|January 7, 2021
VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancersHiromi Watanabe, Eiki Ichihara, Hiroe Kayatani, et al.
Internal Medicine (Tokyo, Japan)|May 21, 2025
A Prompt Diagnosis of Ascites and Dramatic Effect of Alectinib for Advanced Lung Adenocarcinoma Harboring EML4-ALK Fusion: A Case ReportTakahiro Baba, Hirofumi Inoue, Hiromi Matsuoka, et al.
Lung Cancer (Amsterdam, Netherlands)|November 22, 2021
A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancerHiroyuki Yasuda, Eiki Ichihara, Jun Sakakibara-Konishi, et al.
International Journal of Clinical Oncology|October 13, 2021
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)Yukari Tsubata, Kana Watanabe, Ryota Saito, et al.
Japanese Journal of Clinical Oncology|February 23, 2025
Multicenter, open-label, randomized, controlled study to test the utility of electronic patient-reported outcome monitoring in patients with unresectable advanced cancers or metastatic/recurrent solid tumorsNaruto Taira, Naomi Kiyota, Yuichiro Kikawa, et al.
Cancer Immunology Research|July 8, 2022
CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung CancerKazuya Nishii, Kadoaki Ohashi, Shuta Tomida, et al.
Scientific Reports|January 19, 2026
Variations in the perceived value of anti-SARS-CoV-2 therapeutics based on physicians' clinical backgroundsAkihiko Hagiwara, Kosaku Komiya, Yuichiro Shindo, et al.
Antibiotics (Basel, Switzerland)|March 28, 2025
Influence of Educational Films on Antiviral Prescription for COVID-19: Insights from Web-Based Survey in JapanKosaku Komiya, Akihiko Hagiwara, Yuichiro Shindo, et al.
Cancer Science|June 2, 2026
Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr-Mutant Lung Cancer Mouse ModelTakaaki Tanaka, Masato Fujitani, Masataka Taoka, et al.
The European Respiratory Journal|April 1, 2022
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trialKohei Otsubo, Junji Kishimoto, Masahiko Ando, et al.
Pageof 18